|
|
Barkley's unique jail time |
Close Admin：tanyunfei Time：2009-3-10 Views: 91 |
|
|
| Schering-Plough will add strength in the prized area of biologic drugs, which are made from living cells. It will also give Merck one of the world's biggest animal health businesses and a sizable consumer health division that includes products such as allergy pill Claritin, Dr. Scholl's foot products and the Coppertone sun-care line.
Merck Chairman and CEO Richard Clark told The Associated Press the company will be "well-positioned for sustainable growth through scientific innovation."
Big drugmakers are facing slumping sales as the blockbuster drugs of the 1990s lose patent protection, complicated by a dearth of new drugs. Schering-Plough, however, has patent protection for key products until the middle of the next decade and what is considered one of the best product pipelines.
Still, analyst Steve Brozak of WBB Securities said the deal is mainly about Merck "buying revenue and buying earnings."
"It's a good short-term fix, but it unfortunately makes it more complicated for the long term," Brozak said.
|
|
|
|
|
|
Call Us:+1268 562-2888 +1268 562-6662
Your present position: 
